These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 9328159)

  • 1. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
    Gerrits CJ; de Jonge MJ; Schellens JH; Stoter G; Verweij J
    Br J Cancer; 1997; 76(7):952-62. PubMed ID: 9328159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical use of topoisomerase I inhibitors in anticancer treatment.
    Rodriguez-Galindo C; Radomski K; Stewart CF; Furman W; Santana VM; Houghton PJ
    Med Pediatr Oncol; 2000 Oct; 35(4):385-402. PubMed ID: 11025469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan].
    Bonneterre J
    Bull Cancer; 1995 Aug; 82(8):623-8. PubMed ID: 7492818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology.
    Vassal G; Pondarré C; Boland I; Cappelli C; Santos A; Thomas C; Lucchi E; Imadalou K; Pein F; Morizet J; Gouyette A
    Biochimie; 1998 Mar; 80(3):271-80. PubMed ID: 9615866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical applications of the camptothecins.
    Takimoto CH; Wright J; Arbuck SG
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):107-19. PubMed ID: 9748525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
    Emerson DL; Besterman JM; Brown HR; Evans MG; Leitner PP; Luzzio MJ; Shaffer JE; Sternbach DD; Uehling D; Vuong A
    Cancer Res; 1995 Feb; 55(3):603-9. PubMed ID: 7834631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of camptothecin analogs in childhood cancers.
    Bomgaars L; Berg SL; Blaney SM
    Oncologist; 2001; 6(6):506-16. PubMed ID: 11743213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of topoisomerase I-targeting agents.
    Arbuck SG; Takimoto CH
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase I inhibitors in the treatment of colorectal cancer.
    Rothenberg ML; Blanke CD
    Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA-topoisomerase I, a new target for the treatment of neuroblastoma.
    Vassal G; Pondarré C; Cappelli C; Terrier-Lacombe MJ; Boland I; Morizet J; Bénard J; Vénuat AM; Ardouin P; Hartmann O; Gouyette A
    Eur J Cancer; 1997 Oct; 33(12):2011-5. PubMed ID: 9516844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
    Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
    Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase I inhibitors: review and update.
    Rothenberg ML
    Ann Oncol; 1997 Sep; 8(9):837-55. PubMed ID: 9358934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
    Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
    Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topoisomerase I inhibition: a new target or new missiles?
    Verweij J; Schellens JH
    Ann Oncol; 1995 Feb; 6(2):102-4. PubMed ID: 7786815
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies.
    de Jonge MJ; Sparreboom A; Verweij J
    Cancer Treat Rev; 1998 Jun; 24(3):205-20. PubMed ID: 9767735
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical trials with the topoisomerase I inhibitors.
    Burris HA; Rothenberg ML; Kuhn JG; Von Hoff DD
    Semin Oncol; 1992 Dec; 19(6):663-9. PubMed ID: 1334279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines.
    Jonsson E; Dhar S; Jonsson B; Nygren P; Graf W; Larsson R
    Eur J Cancer; 2000 Oct; 36(16):2120-7. PubMed ID: 11044651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.
    Lee JH; Lee JM; Kim JK; Ahn SK; Lee SJ; Kim MY; Jew SS; Park JG; Hong CI
    Arch Pharm Res; 1998 Oct; 21(5):581-90. PubMed ID: 9875499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current perspectives on camptothecins in cancer treatment.
    Dancey J; Eisenhauer EA
    Br J Cancer; 1996 Aug; 74(3):327-38. PubMed ID: 8695345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.